https://www.diabesityrounds.com/a/sglt2-inhibitors-in-adults-aged-75-and-over-cohort-finds-no-increased-harm-versuDiabesity Roundsen2026-10-27T20:47:17.503ZSGLT2 inhibitors in adults aged 75 and over: cohort finds no increased harm versus DPP-4 inhibitorshttps://www.diabesityrounds.com/a/fda-warns-zubb-weight-loss-supplement-contains-hidden-sildenafilDiabesity Roundsen2026-10-27T20:32:12.775ZFDA warns ZUBB weight-loss supplement contains hidden sildenafilhttps://www.diabesityrounds.com/a/triple-agonist-ubt251-lowers-hba1c-in-chinese-adults-with-type-2-diabetes-in-phaDiabesity Roundsen2026-10-27T20:17:18.209ZTriple agonist UBT251 lowers HbA1c in Chinese adults with type 2 diabetes in phase 2 trialhttps://www.diabesityrounds.com/a/cagrisema-in-type-2-diabetes-meta-analysis-of-six-trials-shows-hba1c-and-weight-Diabesity Roundsen2026-10-27T20:02:43.895ZCagriSema in type 2 diabetes: meta-analysis of six trials shows HbA1c and weight fallshttps://www.diabesityrounds.com/a/glp-1-ra-use-and-neuropsychiatric-outcomes-in-medicare-adults-with-type-2-diabetDiabesity Roundsen2026-10-26T20:02:21.689ZGLP-1 RA use and neuropsychiatric outcomes in Medicare adults with type 2 diabetes